With Zyrtec In Front, Consumer Segment Leads J&J’s Performance
This article was originally published in The Tan Sheet
Executive Summary
Sales of Zyrtec helped Johnson & Johnson's consumer business offset the impact of generics on its prescription drug division in its latest earnings period
You may also be interested in...
J&J OTC Business Returns To Double-Digit U.S. Growth In Q1
The domestic OTC/nutritionals business grew more than 14% in the first quarter on the strength of McNeil products returning to market and a severe cold and flu season. Johnson & Johnson’s consumer performance exceeded some market analyst estimates.
J&J OTC Business Returns To Double-Digit U.S. Growth In Q1
The domestic OTC/nutritionals business grew more than 14% in the first quarter on the strength of McNeil products returning to market and a severe cold and flu season. Johnson & Johnson’s consumer performance exceeded some market analyst estimates.
Zyrtec Launch Brings Big Boost To Johnson & Johnson, But Competition Grows
Johnson & Johnson's OTC sales jumped 27 percent to $1.6 billion in the firm's first earnings period with allergy medication Zyrtec (cetirizine 5 mg) available over the counter, according to J&J